Monopar Therapeutics
MNPR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001645469
In the last 90 days, Monopar Therapeutics insiders filed 0 open-market purchases and 4 sales; 95 institutions reported holding it in 13F filings for Q2 2026, worth $576.1M in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding Monopar Therapeutics changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 10 | 9 | −1 |
| Shares | 187.5K | 198.4K | +10.9K (+5.8%) |
| Value | $1.10M | $964.4K | −$139.7K (−12.7%) |
New holders (0)
Institutions that held Monopar Therapeutics at the end of Q3 2021 but not at the end of Q2 2021.
None.
Sold out (1)
Institutions that held Monopar Therapeutics at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Paragon Wealth Strategies, LLC | 58 | $0 |